{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:40:19Z","timestamp":1789191619622,"version":"build-2803163510"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2011,1,28]],"date-time":"2011-01-28T00:00:00Z","timestamp":1296172800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0016412","type":"journal-article","created":{"date-parts":[[2011,1,28]],"date-time":"2011-01-28T22:02:42Z","timestamp":1296252162000},"page":"e16412","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":47,"title":["Use of Non-Steroidal Anti-Inflammatory Drugs and Prostate Cancer Risk: A Population-Based Nested Case-Control Study"],"prefix":"10.1371","volume":"6","author":[{"given":"Salaheddin M.","family":"Mahmud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo L.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Skarsgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Tonita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armen G.","family":"Aprikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,1,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/0003-4819-146-5-200703060-00010","article-title":"Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force.","volume":"146","author":"A Rostom","year":"2007","journal-title":"Ann Intern Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/gast.2003.50008","article-title":"Protective association of aspirin\/NSAIDs and esophageal cancer: a systematic review and meta-analysis.","volume":"124","author":"DA Corley","year":"2003","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1054\/bjoc.2000.1709","article-title":"Breast cancer and NSAID use: a meta-analysis.","volume":"84","author":"SA Khuder","year":"2001","journal-title":"Br J Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/ijc.25186","article-title":"Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: A meta-analysis.","volume":"127","author":"SM Mahmud","year":"2010","journal-title":"International Journal of Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1074\/jbc.275.15.11397","article-title":"The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.","volume":"275","author":"AL Hsu","year":"2000","journal-title":"J Biol Chem"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(01)01255-9","article-title":"The role of cyclooxygenase-2 in prostate cancer.","volume":"58","author":"A Kirschenbaum","year":"2001","journal-title":"Urology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G","article-title":"Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma.","volume":"42","author":"S Gupta","year":"2000","journal-title":"Prostate"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ijc.2910570208","article-title":"Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors.","volume":"57","author":"AA Chaudry","year":"1994","journal-title":"Int J Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/j.seminoncol.2004.03.044","article-title":"COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer.","volume":"31","author":"AL Sabichi","year":"2004","journal-title":"Semin Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.5489\/cuaj.1129","article-title":"Nonsteroidal anti-inflammatory drugs and prostate cancer: A systematic review of the literature and meta-analysis.","volume":"3","author":"S Jafari","year":"2009","journal-title":"Journal of the Canadian Urological Association"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.bjc.6601416","article-title":"Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis.","volume":"90","author":"S Mahmud","year":"2004","journal-title":"Br J Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.cej.0000180665.04335.de","article-title":"Aspirin and the risk of prostate cancer.","volume":"15","author":"C Bosetti","year":"2006","journal-title":"Eur J Cancer Prev"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/jnci\/djk132","article-title":"A Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer Incidence.","volume":"99","author":"EJ Jacobs","year":"2007","journal-title":"Journal of the National Cancer Institute"},{"key":"ref14","first-page":"1108","article-title":"Aspirin use in relation to risk of prostate cancer.","volume":"11","author":"MF Leitzmann","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00001648-199403000-00003","article-title":"Aspirin use and lung, colon, and breast cancer incidence in a prospective study.","volume":"5","author":"DM Schreinemachers","year":"1994","journal-title":"Epidemiology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1136\/bmj.299.6710.1247","article-title":"Aspirin use and chronic diseases: a cohort study of the elderly.","volume":"299","author":"A Paganini-Hill","year":"1989","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1015788502099","article-title":"Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US.","volume":"13","author":"LA Habel","year":"2002","journal-title":"Cancer Causes Control"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/01.cej.0000197451.02604.25","article-title":"Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population.","volume":"15","author":"SM Mahmud","year":"2006","journal-title":"Eur J Cancer Prev"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/(SICI)1097-0215(19980812)77:4<511::AID-IJC6>3.0.CO;2-X","article-title":"Non-steroidal anti-inflammatory drugs and prostate cancer progression.","volume":"77","author":"AE Norrish","year":"1998","journal-title":"Int J Cancer"},{"key":"ref20","first-page":"295","article-title":"Health Services Databases in Saskatchewan.","author":"W Downey","year":"2007"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/oxfordjournals.aje.a117057","article-title":"Menopausal hormone usage and breast cancer in Saskatchewan: a recordlinkage cohort study.","volume":"139","author":"HA Risch","year":"1994","journal-title":"Am J Epidemiol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1008965617078","article-title":"Prostate cancer in Saskatchewan Canada, before and during the PSA era.","volume":"11","author":"D Skarsgard","year":"2000","journal-title":"Cancer Causes Control"},{"key":"ref23","article-title":"Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.","author":"JM Tonita","year":"2008","journal-title":"Cancer Causes and Control"},{"key":"ref24","article-title":"Defining and Validating Chronic Diseases: An Administrative Data Approach.","author":"L Lix","year":"2006"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/oxfordjournals.aje.a116398","article-title":"Selection of Controls in Case-Control Studies: III. Design Options.","volume":"135","author":"S Wacholder","year":"1992","journal-title":"Am J Epidemiol"},{"key":"ref26","article-title":"ATC Index With DDDs.","year":"2002"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/oxfordjournals.aje.a009758","article-title":"Confounding by indication: an example of variation in the use of epidemiologic terminology.","volume":"149","author":"M Salas","year":"1999","journal-title":"Am J Epidemiol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ijc.11250","article-title":"Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer.","volume":"106","author":"L Perron","year":"2003","journal-title":"Int J Cancer"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.aje.a116206","article-title":"Tests for Trend and Dose Response: Misinterpretations and Alternatives.","volume":"135","author":"M Maclure","year":"1992","journal-title":"Am J Epidemiol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/oxfordjournals.aje.a113189","article-title":"Induction and latent periods.","volume":"114","author":"KJ Rothman","year":"1981","journal-title":"Am J Epidemiol"},{"key":"ref31","article-title":"Modern Epidemiology.","author":"KJ Rothman","year":"1998"},{"key":"ref32","first-page":"559","article-title":"Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review).","volume":"13","author":"RE Harris","year":"2005","journal-title":"Oncology Reports"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00045391-200405000-00002","article-title":"A population-based cohort study of mortality among users of ibuprofen in Denmark.","volume":"11","author":"L Lipworth","year":"2004","journal-title":"Am J Ther"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0895-4356(98)00152-8","article-title":"Adjusted odds ratios under nondifferential misclassification: application to prostate cancer.","volume":"52","author":"PA Godley","year":"1999","journal-title":"J Clin Epidemiol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/aje\/kwg062","article-title":"Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it.","volume":"157","author":"NS Weiss","year":"2003","journal-title":"Am J Epidemiol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1158\/1055-9965.EPI-07-0777","article-title":"Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer.","volume":"16","author":"EA Platz","year":"2007","journal-title":"Cancer Epidemiology, Biomarkers and Prevention"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/pds.1619","article-title":"Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database.","volume":"17","author":"C Varas-Lorenzo","year":"2008","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1467-985X.2004.00349.x","article-title":"Multiple-bias modelling for analysis of observational data.","volume":"168","author":"S Greenland","year":"2005","journal-title":"Journal of the Royal Statistical Society Series A"},{"key":"ref39","article-title":"Aboriginal Population Profile, 2006 Census.","year":"2008","journal-title":"Statistics Canada"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/S0022-5347(05)64277-2","article-title":"Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk.","volume":"168","author":"J Irani","year":"2002","journal-title":"J Urol"},{"key":"ref41","first-page":"39","article-title":"The enigma of prostate cancer: An epidemiologic survey of the etiological models of prostate cancer.","volume":"3","author":"SM Mahmud","year":"2007","journal-title":"International Journal of Cancer Prevention"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0165-6147(96)01017-6","article-title":"A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes.","volume":"18","author":"JC Frolich","year":"1997","journal-title":"Trends in Pharmacological Sciences"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1535-7163.MCT-05-0520","article-title":"RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor.","volume":"5","author":"BA Narayanan","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djj206","article-title":"Cyclooxygenase-2 (COX-2)-Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors.","volume":"98","author":"S Grosch","year":"2006","journal-title":"Journal of the National Cancer Institute"},{"key":"ref45","first-page":"2203","article-title":"E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse.","volume":"60","author":"WJ Wechter","year":"2000","journal-title":"Cancer Res"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/pros.20834","article-title":"Effects of non-selective non-steroidal anti-inflammatory drugs on the aggressiveness of prostate cancer.","volume":"68","author":"DC Stock","year":"2008","journal-title":"The Prostate"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","article-title":"Nonsteroidal Anti-Inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues.","volume":"94","author":"MJ Thun","year":"2002","journal-title":"Journal of the National Cancer Institute"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0016412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:14:09Z","timestamp":1588965249000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0016412"}},"subtitle":[],"editor":[{"given":"Syed","family":"Aziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,1,28]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,1,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0016412","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,28]]}}}